Literature DB >> 26845509

Meta-analysis requires independent observations and freedom from bias.

Michael B Bracken1.   

Abstract

Mesh：

Year:  2016        PMID： 26845509      PMCID： PMC4876173          DOI： 10.1111/bcp.12898

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  19 in total

1.  Meta-analysis requires independent observations and freedom from bias.

Authors:  Michael B Bracken
Journal:  Br J Clin Pharmacol       Date:  2016-03-23       Impact factor: 4.335

2.  The use of central nervous system active drugs during pregnancy.

Authors:  Bengt Källén; Natalia Borg; Margareta Reis
Journal:  Pharmaceuticals (Basel)       Date:  2013-10-10

3.  Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian Mother and Child Cohort Study.

Authors:  Hedvig Nordeng; Marleen M H J van Gelder; Olav Spigset; Gideon Koren; Adrienne Einarson; Malin Eberhard-Gran
Journal:  J Clin Psychopharmacol       Date:  2012-04       Impact factor: 3.153

4.  Outcomes of prenatal antidepressant exposure.

Authors:  Gregory E Simon; Michael L Cunningham; Robert L Davis
Journal:  Am J Psychiatry       Date:  2002-12       Impact factor: 18.112

Review 5.  The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta-analysis.

Authors:  Anick Bérard; Noha Iessa; Sonia Chaabane; Flory T Muanda; Takoua Boukhris; Jin-Ping Zhao
Journal:  Br J Clin Pharmacol       Date:  2016-01-26       Impact factor: 4.335

6.  Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects.

Authors:  Sura Alwan; Jennita Reefhuis; Sonja A Rasmussen; Richard S Olney; Jan M Friedman
Journal:  N Engl J Med       Date:  2007-06-28       Impact factor: 91.245

7.  Antidepressant use in pregnancy and the risk of cardiac defects.

Authors:  Krista F Huybrechts; Kristin Palmsten; Jerry Avorn; Lee S Cohen; Lewis B Holmes; Jessica M Franklin; Helen Mogun; Raisa Levin; Mary Kowal; Soko Setoguchi; Sonia Hernández-Díaz
Journal:  N Engl J Med       Date:  2014-06-19       Impact factor: 91.245

8.  Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design.

Authors:  Kari Furu; Helle Kieler; Bengt Haglund; Anders Engeland; Randi Selmer; Olof Stephansson; Unnur Anna Valdimarsdottir; Helga Zoega; Miia Artama; Mika Gissler; Heli Malm; Mette Nørgaard
Journal:  BMJ       Date:  2015-04-17

9.  Combined use of selective serotonin reuptake inhibitors and sedatives/hypnotics during pregnancy: risk of relatively severe congenital malformations or cardiac defects. A register study.

Authors:  Margareta Reis; Bengt Källén
Journal:  BMJ Open       Date:  2013-02-19       Impact factor: 2.692

10.  Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study.

Authors:  Lars Henning Pedersen; Tine Brink Henriksen; Mogens Vestergaard; Jørn Olsen; Bodil Hammer Bech
Journal:  BMJ       Date:  2009-09-23
View more
  3 in total

1.  Meta-analysis requires independent observations and freedom from bias.

Authors:  Michael B Bracken
Journal:  Br J Clin Pharmacol       Date:  2016-03-23       Impact factor: 4.335

Review 2.  Effect of mannose-binding lectin gene polymorphisms on the risk of rheumatoid arthritis: Evidence from a meta-analysis.

Authors:  Jinjian Xu; Gang Chen; Zhen Yan; Mochang Qiu; Wentao Tong; Xiaobin Zhang; Li Zhang; Yimin Zhu; Keqi Liu
Journal:  Int J Rheum Dis       Date:  2021-01-17       Impact factor: 2.454

3.  Paroxetine use during pregnancy and the risk of cardiac defects.

Authors:  Anick Bérard; Sonia Chaabane; Flory T Muanda; Takoua Boukhris; Jinping Zhao
Journal:  Br J Clin Pharmacol       Date:  2016-05-20       Impact factor: 4.335
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.